A U.S. biotech firm has announced that a subsidiary has won a $4.6 million dollar contract in research funding from the Russian Industry and Trade Ministry, barely a week after announcing an earlier funding agreement with Moscow, a medical news website reported.
"Our goal is to advance two of our product candidates into the clinic in the coming year," Michael Fonstein, CEO and president of Cleveland BioLabs subsidiary Panacela said in a statement. "We are honored to partner with the ministry to support a substantial part of our clinical development program."
Under the three-year contract, the Russian ministry has agreed to match Panacela's funding for clinical and preclinical studies of its cancer vaccine Mobilan, News-Medical.net reported Wednesday.
Ties between Panacela and the Russian government date back to when the firm was founded in 2011 as a joint venture between majority owner Cleveland BioLabs and Russia's state-run investment firm Rusnano, the website said.
On Oct. 16, Cleveland BioLabs announced that it had been awarded $4.6 million by the Russian Industry and Trade Ministry to fund studies into Entolimod, another potential cancer treatment.
A Message from The Moscow Times:
Dear readers,
We are facing unprecedented challenges. Russia's Prosecutor General's Office has designated The Moscow Times as an "undesirable" organization, criminalizing our work and putting our staff at risk of prosecution. This follows our earlier unjust labeling as a "foreign agent."
These actions are direct attempts to silence independent journalism in Russia. The authorities claim our work "discredits the decisions of the Russian leadership." We see things differently: we strive to provide accurate, unbiased reporting on Russia.
We, the journalists of The Moscow Times, refuse to be silenced. But to continue our work, we need your help.
Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just $2. It's quick to set up, and every contribution makes a significant impact.
By supporting The Moscow Times, you're defending open, independent journalism in the face of repression. Thank you for standing with us.
Remind me later.
